Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

Find the latest Vivani Medical, Inc. (VANI) stock quote, history, news and other vital information to help you with your stock trading and investing.

The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $4.99 per share. The engine maker posted revenue of $8.64 billion in the period, also exceeding Street ...